Acro Biomedical (ACBM) EBIT Margin (2017 - 2022)

Acro Biomedical has reported EBIT Margin for 6 years, with the latest figure at 1092.75% in Q4 2022.

• On a quarterly basis, EBIT Margin fell 44850.0% year-over-year to 1092.75% in Q4 2022; TTM through Sep 2023 was 3533.57%, a 177245.0% decrease from a year earlier, with the FY2022 full-year figure at 2409.98%, down 176751.0% from the prior year.
• EBIT Margin was 1092.75% for Q4 2022 at Acro Biomedical, up from 1316.11% in the prior quarter.
• The five-year high for EBIT Margin was 11.85% in Q1 2020, with the low at 1316.11% in Q1 2022.
• Average EBIT Margin over 5 years is 298.49%, with a median of 38.98% recorded in 2019.
• The sharpest annual moves came in 2018 and 2022: EBIT Margin sank 1251 bps in 2018, then sank 125883 bps in 2022.
• Over 5 years, EBIT Margin stood at 6.96% in 2018, then plunged by 460 bps to 38.98% in 2019, then surged by 130 bps to 11.85% in 2020, then slumped by 5534 bps to 644.25% in 2021, then plunged by 70 bps to 1092.75% in 2022.
• The last three EBIT Margin figures came in at 1092.75% (Q4 2022), 1316.11% (Q1 2022), and 644.25% (Q4 2021), per Business Quant data.